Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results

Wednesday, March 6, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Merrimack Pharmaceuticals, Inc.

Selected Balance Sheet Data (unaudited)

(in thousands)

December 31, 2018

December 31, 2017

Cash, cash equivalents and marketable securities

$               71,278

$               93,441

Working capital

61,307

75,269

Total assets

88,543

117,326

Total liabilities

29,724

21,042

Total stockholders' equity

58,819

96,284



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store